Erste Group analyst Hans Engel reinstated coverage of Boston Scientific (BSX) with a Buy rating. Boston Scientific has “very innovative products” and its positive business development should continue in the longer term, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Growth Potential Bolstered by AGENT DCB Expansion and Reimbursement Developments
- Boston Scientific Stockholders Approve Key Governance Proposals
- Corporate America Slashing Costs As Tariff Uncertainty Abounds
- Boston Scientific price target raised to $125 from $118 at Barclays
- Boston Scientific says second phase of ADVANTAGE AF study met primary endpoints